What should I do if I become resistant to Satclizumab (Anxupin)?

Satralizumab (Satralizumab) is a drug that is widely studied and used to treat neuromyelitis optica (NMOSD). According to clinical trial results, satelizumab has shown good results in controlling and reducing NMOSD attacks. If drug resistance occurs after use, the following methods can be considered:

1. Change drugs: You can try to change other drugs that target anti-coagulation factor X-activating antibodies, such as argatroban, rivaroxaban, etc., or use other types of immunosuppressants.

2. Combined treatment: Consider using other drugs in combination for treatment, such as anti-inflammatory drugs, immunomodulators, etc.

3. Adjust the dosage: If the drug resistance is not too serious, you can try to adjust the dosage of the drug to see if it can alleviate the symptoms.

4. Seek the advice of a professional doctor: If none of the above methods can alleviate the symptoms, it is recommended to seek the advice of a professional doctor. Since everyone has a different physique and has different drug resistance reactions, the doctor will formulate an appropriate treatment plan according to the specific situation.

The original drug satlizumab has been launched in China, sold under the brand name Anshiping, and is included in medical insurance. Only patients who meet the indications can be reimbursed. The specification is120mg (1ml) per box The price may be more than RMB 10,000, which is still relatively expensive; the price of each box of the original drug Saterizumab sold overseas is more than $10,000 (the price may fluctuate due to the exchange rate). The ingredients of the original drug sold domestically and abroad are basically the same. There are currently no generic versions of satlizumab available on the market.